CSIMarket Company Name, Ticker, Suppliers, else..
 

Io Biotech Inc   (NASDAQ: IOBT)

Io Biotech Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

IOBT Sales vs. its Competitors Q3 2025


Comparing the current results to its competitors, Io Biotech Inc reported Revenue decrease in the 3 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 52.88 %, recorded in the same quarter.

• List of IOBT Competitors





Revenue Growth Comparisons




Net Income Comparison

Io Biotech Inc recorded a net loss, as well as most of its competitors.

<<  IOBT Stock Performance Comparisons


Io Biotech Inc 's Comment on Competition and Industry Peers


The company operates in a competitive environment where other entities may discover, develop, or commercialize products more rapidly or effectively. Competitors may develop and market products similar or identical to those of the company if it cannot secure and maintain adequate intellectual property protection. The company competes with firms currently producing or conducting clinical development of treatments for the same disease indications and treatment modalities.



*Market share is calculated based on total revenue.

  News about Io Biotech Inc Contracts

Unraveling the Dual Mechanism of Action: A Promising Breakthrough in Cancer Immunotherapy

April 9, 2024
 :This article presents an in-depth analysis of the groundbreaking research conducted by IO Biotech, as presented at AACR 2024. The focus revolves around the new data provided on IO102-IO103, a novel cancer vaccine that showcases a dual mechanism of action (MOA). This comprehensive review aims to shed light on the significance of this dual MOA and the potential impact it may have on cancer treatment.Cancer immunotherapy has emerged as a revolutionary approach in the fight against cancer, harnessing the power of the immune system to target tumor cells. IO Biotech, a leading biotechnology company, has made significant strides in this field, particularly with their lead cancer vaccine, IO102-IO103. Recently pres...





Publicly Traded Peers of Io Biotech Inc




Zymeworks Inc
Share Performance



+24.01%
This Quarter
Zymeworks Inc
Profile

Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.

More about Zymeworks Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,233.373 mill. $ 81.263 mill. $ -102.656 mill.


Nextcure Inc
Share Performance



+29.91%
Over The Past 5 Days
Nextcure Inc
Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 41.076 mill. $ - mill. $ -54.664 mill.


Nuvalent Inc
Share Performance



+0.05%
Over The Past 5 Days
Nuvalent Inc
Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 9,751.979 mill. $ - mill. $ -450.074 mill.


Nurix Therapeutics Inc
Share Performance



+0.80%
30 Days
Nurix Therapeutics Inc
Profile

Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.

More about Nurix Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,812.658 mill. $ 36.766 mill. $ -341.351 mill.


Novabridge Biosciences
Share Performance



-57.85%
This Year
Novabridge Biosciences
Profile

The company develops drug candidates and conducts related research and development activities in China.

More about Novabridge Biosciences's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 172.377 mill. $ - mill. $ -88.340 mill.

44 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Io Biotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Io Biotech Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.